コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rease the risk of glaucoma for patients with retinal disease.
2 stem/progenitor cell-based interventions for retinal disease.
3 individuals aged 63 years and older without retinal disease.
4 on of genes, including genes associated with retinal disease.
5 review the role of UWFA in the management of retinal disease.
6 ng cis-regulatory variants in the context of retinal disease.
7 the retina may have therapeutic effects for retinal disease.
8 to an innate immune response in neovascular retinal disease.
9 e genes in this network are risk factors for retinal disease.
10 n-related changes in vivo in mouse models of retinal disease.
11 amounts prior to development of most severe retinal disease.
12 zation for stroke among Ontario seniors with retinal disease.
13 the multifocal ERG is superior in localized retinal disease.
14 r oedema, such as uveitis, diabetes or other retinal disease.
15 em cell therapy to be a viable treatment for retinal disease.
16 tants lead to loss of Cav1.4 function and to retinal disease.
17 c indicator for patients with this inherited retinal disease.
18 and the generation of mouse models of human retinal disease.
19 estoring sight to individuals suffering from retinal disease.
20 a therapeutic option for transplantation in retinal disease.
21 o(-/-) were reminiscent of findings in human retinal disease.
22 rphic mutations in human LAMA1 could lead to retinal disease.
23 he use of SD-OCT in detecting and diagnosing retinal disease.
24 ndergoing surgery for cataract, glaucoma, or retinal disease.
25 s of relevance to both Mendelian and complex retinal disease.
26 at might account for phenotypic diversity in retinal disease.
27 investigate the genetic causes of inherited retinal disease.
28 m-cell therapy a viable treatment for select retinal disease.
29 herapies that aim to alleviate ABCA4-related retinal disease.
30 pectralis OCT, in subjects without any known retinal disease.
31 o-associated virus-mediated gene therapy for retinal disease.
32 eurologic disorders, including glaucoma, and retinal disease.
33 ns in rodent models of the visual system and retinal disease.
34 e variants of angle closure in patients with retinal disease.
35 nt efficacy in patients and animal models of retinal disease.
36 nization of the visual system in people with retinal disease.
37 for the application of hNPC(ctx) in treating retinal disease.
38 enetic analysis, and treatment of hereditary retinal disease.
39 MacTel) is a rare neurovascular degenerative retinal disease.
40 therapeutically modulating immune aspects in retinal disease.
41 linical diagnosis and assessing treatment of retinal disease.
42 apies aimed at photoreceptor regeneration in retinal disease.
43 ional potential of these drugs for inherited retinal disease.
44 genic mutation in MAPKAPK3 associated with a retinal disease.
45 nificant therapies for currently untreatable retinal disease.
46 e of autologous cells for transplantation in retinal disease.
47 zed iPSC-based transplantation therapies for retinal disease.
48 get for optogenetic restoration of vision in retinal disease.
49 l be safe and effective for individuals with retinal diseases.
50 ducted at a tertiary referral eye center for retinal diseases.
51 ortant for the management of a wide range of retinal diseases.
52 ntanglement of the exact role MMPs in ocular/retinal diseases.
53 to retina scar formation in many devastating retinal diseases.
54 ues of research into the treatment of common retinal diseases.
55 ular diseases, including recently in certain retinal diseases.
56 re favorably with costs of therapy for other retinal diseases.
57 of vision loss in ischemic and inflammatory retinal diseases.
58 ic target in the treatment of human vascular retinal diseases.
59 costs for cataract surgery and treatment of retinal diseases.
60 rtance in the pathophysiology of a number of retinal diseases.
61 ponse to light and is involved in congenital retinal diseases.
62 retinal neuronal and vascular pathologies in retinal diseases.
63 ) in eyes receiving ranibizumab for 3 common retinal diseases.
64 tment under active investigation in multiple retinal diseases.
65 tion in patients suffering from degenerative retinal diseases.
66 w insights into the roles of PNR mutation in retinal diseases.
67 agents are now used for treatment of common retinal diseases.
68 ness and other closely related nonstationary retinal diseases.
69 DME) compared with diabetic patients without retinal diseases.
70 apy holds great promise for the treatment of retinal diseases.
71 ne therapy by scAAV2/8 delivery for dominant retinal diseases.
72 ceptors is a common endpoint in degenerative retinal diseases.
73 he features of AMD as well as those of other retinal diseases.
74 as grown since its first use in glaucoma and retinal diseases.
75 play several key roles in normal and various retinal diseases.
76 ion may provide therapeutic benefit for such retinal diseases.
77 ough which to study genetic heterogeneity in retinal diseases.
78 dpoint may be warranted in treating ischemic retinal diseases.
79 ents for the therapy of angiogenesis-related retinal diseases.
80 e photoreceptor organization and its role in retinal diseases.
81 lls for cell-based therapies of degenerative retinal diseases.
82 s and may play a role in the pathogenesis of retinal diseases.
83 apeutic effects against certain degenerative retinal diseases.
84 e RPE/phagocyte interaction in AMD and other retinal diseases.
85 a new approach for the treatment of blinding retinal diseases.
86 ded novel insights in clinical evaluation of retinal diseases.
87 r range of findings to those of other severe retinal diseases.
88 cted by central or peripheral scotoma due to retinal diseases.
89 ction can reduce irreversible blindness from retinal diseases.
90 a (RP) is a heterogeneous group of inherited retinal diseases.
91 m photoreceptor cell degeneration or related retinal diseases.
92 PUFAs among patients with different types of retinal diseases.
93 ecedented details of vascular involvement in retinal diseases.
94 ar telangiectasia, neovascular AMD and other retinal diseases.
95 cizumab use increased each year for diabetic retinal disease (2.4 injections/1000 patients with diabe
101 quencing in 28 individuals with "cone-first" retinal disease and clinical features atypical for ABCA4
102 RPE function, modeling of RPE dysfunction in retinal disease and in vitro evaluation of new therapies
104 fected with two different forms of inherited retinal disease and should be useful as a means of asses
105 tform genetic testing strategy for inherited retinal disease and to describe its performance in 1000
108 ious stem cell-based approaches for treating retinal diseases and discuss future directions and chall
109 signature genes are excellent candidates for retinal diseases and for physiological investigations (e
110 exosomes in the molecular pathophysiology of retinal diseases and help identify potential therapeutic
111 required to treat Muller cell deficiency in retinal diseases and in other parts of the CNS associate
112 ncreased each year in patients with diabetic retinal diseases and retinal vein occlusions (both <0.1
113 Mutations in RDS cause rod and cone-dominant retinal disease, and it is well established that both ce
114 onia, pathological gastro-esophageal reflux, retinal disease, and sinus-node dysfunction, whereas rel
116 blood vessel growth is a key feature of many retinal diseases, and recently, anti-VEGF therapy has be
117 inal changes in animal models of neovascular retinal disease approximately 3-4-fold longer than unmod
118 enes traditionally associated with syndromic retinal disease are increasingly found to cause nonsyndr
123 on of common variants in the ABCA4 gene with retinal disease, assessed by a score-based variance-comp
124 imal model for studying the visual cycle and retinal diseases associated with chromophore regeneratio
125 in developing anti-complement therapies for retinal diseases associated with complement activation.
126 ld identify new molecular therapies to treat retinal diseases associated with ER protein misfolding.
127 athies are a group of monogenetic or complex retinal diseases associated with high unmet medical need
129 These inhibitors may be beneficial against retinal diseases associated with the loss of RPE cells.
132 ut age-related macular degeneration (AMD) or retinal disease at fundus examination were matched for e
135 This study showed that ERM is not a static retinal disease but a dynamic condition in which retinal
136 ons suggests that MPDZ plays a role in human retinal disease, but the precise nature of this role rem
137 l structure and function in rodent models of retinal disease, but translation to clinical practice wi
138 en implicated in the pathogenesis of various retinal diseases, but their basic function and cellular
139 s were analyzed for pigmentation defects and retinal disease by histology, immunohistochemistry, and
140 ngiography to differentiate optic nerve from retinal disease can be very helpful in formulating a dif
143 encing (NGS), we screened mutations in known retinal disease-causing genes in an RP cohort of 35 unre
145 nstrumentation and imaging methods to detect retinal diseases changing indications for surgery, impro
146 rmine the prevalence of CPR-type diplopia in retinal disease clinic patients with ERM and to determin
147 sectional study of 31 patients with ERM from retinal disease clinics to determine the prevalence of C
149 R-type diplopia in patients with ERM seen in retinal disease clinics, and whether or not clinical fin
150 understanding of the pathobiologic basis of retinal diseases, coupled with growth of gene transfer a
152 ese clinical efforts for several significant retinal diseases, describe the challenges involved and d
154 The age at onset and natural progression of retinal disease differs greatly between syndromic and no
158 ut also identify a form of pathology wherein retinal disease first manifests at the POS-RPE junction.
159 cataract surgery in patients with coexisting retinal disease, focusing on factors that are important
161 ty of AAVs combined with the large number of retinal disease genes exceeding that capacity make the d
162 GS), we screened mutations in over 200 known retinal disease genes in a cohort of 12 unrelated Uyghur
166 l was designed, which incorporated 195 known retinal disease genes, including 61 known RP genes.
169 e performance of these programs in eyes with retinal diseases has not been independently evaluated.
170 nsights into the pathophysiology of advanced retinal disease highlighting a role for Muller cells and
171 presence of these cells in mouse models for retinal disease; however, only limited aspects of their
173 (2.4 injections/1000 patients with diabetic retinal disease in 2009 to 13.6 per 1000 in 2015) while
174 tic neuropathy in 3, corneal opacities in 3, retinal disease in 3, and undetermined in 5) that preven
175 on interventions to minimize progression of retinal disease in diabetic patients undergoing cataract
177 sted that apoptosis contributed minimally to retinal disease in MCMV-infected eyes of MAIDS-10 mice.
179 making it the most common cause of heritable retinal disease in this population and MAK-associated RP
180 visual photoresponse and trigger congenital retinal diseases in humans, but GCAP interaction with it
182 reports the prevalence and pattern of vitreo-retinal diseases in the Bhaktapur Glaucoma Study (BGS),
183 kle cell retinopathy, uveitis, and pediatric retinal disease, in turn guiding both diagnosis and mana
185 number of desirable qualities for a model of retinal disease including a large eye and an existing an
186 Several point mutations in rhodopsin cause retinal diseases including congenital stationary night b
187 sels, is a key feature of many proliferative retinal diseases including diabetic retinopathy, retinal
189 reversible vision loss in incurable blinding retinal diseases including retinitis pigmentosa (RP) and
190 degeneration (AMD), 16.1% to treat diabetic retinal diseases (including 0.9% of all injections that
191 following cataract surgery in patients with retinal disease, including uveitis, diabetic macular ede
192 helial dysfunction and death in degenerative retinal diseases, including age-related macular degenera
194 s associated with a broad range of inherited retinal diseases, including Stargardt disease, autosomal
202 of genes that can, when mutated, cause human retinal disease is a powerful means to understand the mo
203 oretinal research, the spectrum of treatable retinal disease is likely to expand significantly in the
208 generation, a neurodegenerative and vascular retinal disease, is the most common cause of blindness i
210 unction that is known to contribute to human retinal diseases like age-related macular degeneration.
211 al and genetic heterogeneity associated with retinal diseases makes stem-cell-based therapies an attr
212 been tested in preclinical animal models of retinal disease, many postnatal stem/progenitor cell pop
215 tic approaches to blocking VEGF signaling in retinal diseases might have unexpected detrimental side
217 cts (n = 3519) and diabetes controls without retinal disease (n = 10557) were matched by age and gend
220 or sophisticated monitoring and diagnosis of retinal diseases, OCTA capable of providing wide-field a
222 lants are now available for the treatment of retinal disease, offering control of macular edema and i
224 , observational study, 20 volunteers with no retinal diseases or risk factors, ranging in age between
225 s of screening for glaucoma, the presence of retinal disease, or decreased acuity in a population-bas
226 acking of visual development, progression of retinal disease, or therapeutic interventions, such as i
227 has been associated with the development of retinal diseases, particularly age-related macular degen
228 Here we characterize the development of the retinal disease phenotype in a genetic model of type 1 d
229 nd provide insights into the pathogenesis of retinal disease phenotypes caused by NR2E3 mutations.
230 (sgRho) vs. intronless cDNA in ameliorating retinal disease phenotypes in a rhodopsin knockout (RKO)
231 nducted on a patient with distinct inherited retinal disease presenting in childhood, with a phenotyp
232 effect of pharmacological PERK inhibition on retinal disease process in the P23H-1 transgenic rat mod
233 ch has the potential to aid in understanding retinal disease processes and will facilitate preclinica
235 s included previously known risk factors for retinal diseases related to oxidative stress, inflammati
238 ion, which were resistant and susceptible to retinal disease, respectively, but which harbored equiva
239 or cause of retinitis pigmentosa, a blinding retinal disease resulting from photoreceptor degeneratio
240 ted eyes, 9 were enucleated, 6 for recurrent retinal disease, resulting in an overall globe salvage r
241 rs in diabetic retinopathy and other chronic retinal diseases, results in vasogenic edema and neural
247 strategies for the treatment of degenerative retinal diseases such as age-related macular degeneratio
248 ve to the intravitreal injection for chronic retinal diseases such as age-related macular degeneratio
251 use of irreversible blindness in a number of retinal diseases such as retinitis pigmentosa (RP) and a
252 entials via retinal circuitry, degenerate in retinal diseases such as retinitis pigmentosa and age re
253 hese ZFNs may be useful for the treatment of retinal diseases such as retinitis pigmentosa, one of th
254 a critical role in normal physiology and in retinal diseases, such as age-related macular degenerati
255 ent a novel class of potential therapies for retinal diseases, such as age-related macular degenerati
256 cumulating for a role of complement in other retinal diseases, such as diabetic retinopathy and proli
257 potential molecular mechanisms of inherited retinal diseases, such as Oguchi disease and Arr1-associ
258 cysts and ERMs were more common in eyes with retinal diseases, such as proliferative diabetic retinop
259 cycle is considered a treatment strategy for retinal diseases, such as Stargardt disease and dry age-
260 characterize cellular structure in inherited retinal disease; such information will be critical for s
261 ell as pathologies observed in age-dependent retinal diseases, suggesting that the responsible gene r
262 risk populations and revealed fewer cases of retinal disease than previously estimated, suggesting un
263 l microvessels isolated from mouse models of retinal disease that exhibit vascular pathology, and unc
264 igmentosa (RP) is an inherited, degenerative retinal disease that leads to blindness for which no the
266 (ACHM) is a congenital, autosomal recessive retinal disease that manifests cone dysfunction, reduced
268 tions have the potential to address blinding retinal diseases that affect hundreds of millions worldw
269 an increased prevalence of both glaucoma and retinal diseases that can affect the visual outcomes aft
270 egeneration, retinitis pigmentosa, and other retinal diseases that can cause pathological changes in
271 ist to differentiate between optic nerve and retinal diseases that can share some common characterist
272 atment of neovascularization associated with retinal diseases that involve pathologic angiogenesis.
273 from the West Indies islands with a peculiar retinal disease, the Martinique crinkled retinal pigment
278 a common pathological factor in degenerative retinal diseases; therefore, identifying novel strategie
279 llowed by reperfusion (IR) to model ischemic retinal disease, this study compares the effects of isch
281 sh Columbia, such as those of the Provincial Retinal Diseases Treatment Program, who had received int
283 cluding visual loss from the optic nerve and retinal disease, visual field loss from retrochiasmal vi
285 -fat diet-induced diabetes in mice can model retinal disease, we weaned mice to chow or a high-fat di
287 cts and patients diagnosed with AMD or other retinal diseases were collected during routine visits vi
288 mplicated in the promotion of ME in ischemic retinal disease, were not elevated by quantitative enzym
289 st of genes that will likely result in human retinal disease when mutated was identified and validate
290 bretinal space are thought to be involved in retinal diseases where low-grade chronic inflammation an
291 rly detection and longitudinal monitoring of retinal diseases where retinal and choroidal hemodynamic
292 iously known to be associated with inherited retinal disease, which harbor biallelic predicted protei
294 m a cohort of 722 individuals with inherited retinal disease, who have had whole-genome sequencing (n
295 iew the evidence for progression of diabetic retinal disease with cataract surgery and critically ana
296 angiectasia (MacTel) is a vision-threatening retinal disease with unknown pathogenesis and no approve
297 of stem/progenitor cell-based approaches for retinal disease, with interpretation and perspective.
298 ated gene therapy for treatment of inherited retinal diseases, with early intervention resulting in t
299 ) systems in the diagnosis and management of retinal diseases, with particular emphasis on choroidal
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。